Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes.

Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A.

Transpl Infect Dis. 2019 Apr;21(2):e13052. doi: 10.1111/tid.13052. Epub 2019 Feb 15.

PMID:
30689291
2.

FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.

Atrash S, Dua I, Buros AF, Van Rhee F, Suva LJ, Thanendrarajan S, Schinke C, Davies F, Morgan G, Zangari M.

Bone. 2019 Apr;121:134-138. doi: 10.1016/j.bone.2018.09.013. Epub 2018 Sep 19.

PMID:
30244157
3.

Comparison of Postbaccalaureate and Baccalaureate Graduates' Performance in First and Second Years of Dental School.

Johnson GM, Buros AF, Lukas RW.

J Dent Educ. 2018 Sep;82(9):929-935. doi: 10.21815/JDE.018.090.

PMID:
30173188
4.

Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago.

Wang SK, Gilchrist A, Loukitcheva A, Plotkin BJ, Sigar IM, Gross AE, O'Donnell JN, Pettit N, Buros A, O'Driscoll T, Rhodes NJ, Bethel C, Segreti J, Charnot-Katsikas A, Singh K, Scheetz MH.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00382-18. doi: 10.1128/AAC.00382-18. Print 2018 Aug.

5.

Efficacy of Intravenous Acetaminophen for Postoperative Analgesia in Primary Total Knee Arthroplasty.

Huang PS, Gleason SM, Shah JA, Buros AF, Hoffman DA.

J Arthroplasty. 2018 Apr;33(4):1052-1056. doi: 10.1016/j.arth.2017.10.054. Epub 2017 Nov 10.

PMID:
29174762
6.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

7.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

8.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C.

Am J Hematol. 2017 Aug;92(8):739-745. doi: 10.1002/ajh.24756. Epub 2017 Jun 1.

9.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

10.

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M.

J Bone Miner Res. 2017 Jun;32(6):1261-1266. doi: 10.1002/jbmr.3111. Epub 2017 Mar 27.

11.

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE.

Blood. 2016 Dec 22;128(25):2919-2930. doi: 10.1182/blood-2016-03-706077. Epub 2016 Oct 28.

12.

Variations in Inpatient Rehabilitation Functional Outcomes Across Centers in the Traumatic Brain Injury Model Systems Study and the Influence of Demographics and Injury Severity on Patient Outcomes.

Dahdah MN, Barnes S, Buros A, Dubiel R, Dunklin C, Callender L, Harper C, Wilson A, Diaz-Arrastia R, Bergquist T, Sherer M, Whiteneck G, Pretz C, Vanderploeg RD, Shafi S.

Arch Phys Med Rehabil. 2016 Nov;97(11):1821-1831. doi: 10.1016/j.apmr.2016.05.005. Epub 2016 May 28.

PMID:
27246623
13.

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.

Clin Cancer Res. 2017 Apr 15;23(8):1981-1987. doi: 10.1158/1078-0432.CCR-16-0235. Epub 2016 Oct 3.

14.

The impact of preexisting illness and substance use on functional and neuropsychological outcomes following traumatic brain injury.

Dahdah MN, Barnes SA, Buros A, Allmon A, Dubiel R, Dunklin C, Callender L, Shafi S.

Proc (Bayl Univ Med Cent). 2016 Jul;29(3):271-6.

15.

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.

Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B.

BMC Bioinformatics. 2015 Feb 25;16:63. doi: 10.1186/s12859-015-0478-3.

Supplemental Content

Support Center